ABT
Not just a milkshake with a giraffe on it
Abbott thought it could swat away a proposed class-action lawsuit over PediaSure. Instead, a federal judge said, “Not so fast.” The case centers on whether Abbott’s marketing for PediaSure Grow & Gain could have led parents to believe the drinks were clinically proven to help kids get taller.
The judge saw the giraffe too
The court’s logic was basically: if you slap a cartoon giraffe next to ruler-like markings on the package, you’re not exactly whispering subtlety. Judge Paul Engelmayer said consumers could reasonably interpret Abbott’s use of “grow” as meaning height growth, while “gain” could point to weight gain. In other words, the packaging allegedly did a lot of the heavy lifting.
Why investors should care
This isn’t a life-or-death blow to Abbott’s business, but it is the kind of nuisance risk that can morph into real cost if the case keeps moving:
- more legal spend
- more discovery drama
- more pressure on consumer trust around a key brand
Abbott says its labeling is appropriate and backed by evidence, and it also argues PediaSure is meant for kids at risk of low weight-for-height measurements. But for now, the lawsuit survives — which means the story isn’t over.
Big picture
Abbott’s stock can shrug off a lot, but brands built on trust are a little like parents at a birthday party: one weird impression can linger. This ruling doesn’t prove misconduct, but it does keep the courtroom spotlight on a product that’s supposed to help children, not generate depositions.